Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.

Salazar N, Carlson JC, Huang K, Zheng Y, Oderup C, Gross J, Jang AD, Burke TM, Lewén S, Scholz A, Huang S, Nease L, Kosek J, Mittelbronn M, Butcher EC, Tu H, Zabel BA.

Mol Ther. 2018 May 2;26(5):1354-1365. doi: 10.1016/j.ymthe.2018.02.030. Epub 2018 Mar 6.

2.

A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease.

Graham KL, Zhang JV, Lewén S, Burke TM, Dang T, Zoudilova M, Sobel RA, Butcher EC, Zabel BA.

PLoS One. 2014 Dec 1;9(12):e112925. doi: 10.1371/journal.pone.0112925. eCollection 2014.

3.

Robust expansion of dendritic cells in vivo by hydrodynamic FLT3L-FC gene transfer.

Tu H, Burke TM, Oderup C, Huang K, Wong K, Lewén S, LaJevic M, Zabel BA.

J Immunol Methods. 2014 Nov;413:69-73. doi: 10.1016/j.jim.2014.07.008. Epub 2014 Jul 24.

4.

Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels.

Berahovich RD, Zabel BA, Lewén S, Walters MJ, Ebsworth K, Wang Y, Jaen JC, Schall TJ.

Immunology. 2014 Jan;141(1):111-22. doi: 10.1111/imm.12176.

5.

Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells.

Monnier J, Lewén S, O'Hara E, Huang K, Tu H, Butcher EC, Zabel BA.

J Immunol. 2012 Jul 15;189(2):956-67. doi: 10.4049/jimmunol.1102871. Epub 2012 Jun 13.

6.

The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells.

Zabel BA, Lewén S, Berahovich RD, Jaén JC, Schall TJ.

Mol Cancer. 2011 Jun 14;10:73. doi: 10.1186/1476-4598-10-73.

7.

CXCR7 protein is not expressed on human or mouse leukocytes.

Berahovich RD, Zabel BA, Penfold ME, Lewén S, Wang Y, Miao Z, Gan L, Pereda J, Dias J, Slukvin II, McGrath KE, Jaen JC, Schall TJ.

J Immunol. 2010 Nov 1;185(9):5130-9. doi: 10.4049/jimmunol.1001660. Epub 2010 Oct 1.

8.

CXCR7 protein expression correlates with elevated mmp-3 secretion in breast cancer cells.

Zabel BA, Miao Z, Lai NL, Wang Y, Lewén S, Berahovich RD, Jaén JC, Schall TJ.

Oncol Lett. 2010 Sep;1(5):845-847. Epub 2010 Sep 1.

9.

Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells.

Löfgren SE, Yin H, Delgado-Vega AM, Sanchez E, Lewén S, Pons-Estel BA, Witte T, D'Alfonso S, Ortego-Centeno N, Martin J, Alarcón-Riquelme ME, Kozyrev SV.

J Rheumatol. 2010 Mar;37(3):574-8. doi: 10.3899/jrheum.090440. Epub 2010 Jan 15.

PMID:
20080916
10.

Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.

Zabel BA, Wang Y, Lewén S, Berahovich RD, Penfold ME, Zhang P, Powers J, Summers BC, Miao Z, Zhao B, Jalili A, Janowska-Wieczorek A, Jaen JC, Schall TJ.

J Immunol. 2009 Sep 1;183(5):3204-11. doi: 10.4049/jimmunol.0900269. Epub 2009 Jul 29.

11.

A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis.

Lewēn S, Zhou H, Hu HD, Cheng T, Markowitz D, Reisfeld RA, Xiang R, Luo Y.

Cancer Immunol Immunother. 2008 Apr;57(4):507-15. Epub 2007 Sep 5.

PMID:
17786443
12.

Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus.

Kozyrev SV, Lewén S, Reddy PM, Pons-Estel B; Argentine Collaborative Group, Witte T; German Collaborative Group, Junker P, Laustrup H, Gutiérrez C, Suárez A, Francisca González-Escribano M, Martín J; Spanish Collaborative Group, Alarcón-Riquelme ME.

Arthritis Rheum. 2007 Apr;56(4):1234-41.

Supplemental Content

Support Center